What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? [electronic resource]
Producer: 20161213Description: 29 p. digitalISSN:- 1534-6269
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- BRCA1 Protein -- genetics
- BRCA2 Protein -- genetics
- Disease-Free Survival
- Female
- Humans
- Mutation
- Ovarian Neoplasms -- drug therapy
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Poly(ADP-ribose) Polymerase Inhibitors -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.